NYSE:DGXHealthcare
Assessing Quest Diagnostics (DGX) Valuation After Launch Of New Myeloma MRD Blood Test
Quest Diagnostics (DGX) just launched Quest Flow Cytometry MRD for Myeloma, a blood based test that measures residual disease in multiple myeloma and offers sensitivity comparable to next generation sequencing at a lower cost.
See our latest analysis for Quest Diagnostics.
Quest Diagnostics’ launch of the new myeloma MRD test comes as momentum has been gradually building, with the share price at US$191.25 and a 30 day share price return of 9.64%, while the 1 year total shareholder return...